LP
BEAM icon

Longaeva Partners’s Beam Therapeutics BEAM Stock Holding History

Longaeva Partners’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$370K Buy
15,518
+3,598
+30% +$99.8K 0.01% 191
2025
Q4 		$330K Buy
+11,920
New +$304K 0.03% 116

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Longaeva Partners's BEAM Position: Q1 2026 in Review

Longaeva Partners increased its Beam Therapeutics (BEAM) stake by 30% in Q1 2026, buying an estimated $99.8K and bringing the position to 15,518 shares worth $370K. The position accounts for 0.01% of the portfolio, ranked #191.

Longaeva Partners first reported a position in BEAM in Q4 2025 and has held it in 2 quarters since. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • Longaeva Partners held 15,518 shares of Beam Therapeutics worth $370K as of Q1 2026.
  • Longaeva Partners bought 3,598 Beam Therapeutics shares in Q1 2026, an estimated $99.8K.
  • Beam Therapeutics made up 0.01% of Longaeva Partners's portfolio in Q1 2026, its #191 holding.
  • Longaeva Partners first reported a position in Beam Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Longaeva Partners's 13F filing for Q1 2026, filed 15 May 2026.